Gastroenterologia y hepatologia · 2014
[Hepatitis B virus reactivation in rituximab-treated patients: incidence and risk factors].
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gutiérrez García María Luisa, Alonso Lopez Sonia, Martín Rios María Dolores, Sanmartin Fenollera Patricia, Agudo Fernandez Sandra, Fernández Rodriguez Conrado Manuel
Аннотация
Hepatitis B virus (HBV) reactivation after chemotherapy regimens is a well-known complication. The incidence and risk factors for HBV reactivation remain to be elucidated. We aimed to determine the incidence and risk factors for HBV reactivation in patients receiving rituximab, and the potential role of the cumulative rituximab dose in HBV reactivation. We retrospectively reviewed 320 patients receiving rituximab in our hospital. Of these, 42 (13.12%) had serological markers of hepatitis B. During follow-up, 21% (9/42) had HBV reactivation. Risk factors for reactivation were HBsAg positivity (p < 0.05), isolated anti-HBc positivity (p < 0.05), marginal zone lymphoma, and Mantle cell lymphoma (p < 0.05). The median rituximab dose tended to be higher in patients with reactivation (p = 0.06).
Предметные рубрики MeSH
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsAutoimmune DiseasesDose-Response Relationship, DrugFemaleHepatitis BHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesHepatitis B virusHumansImmunocompromised HostImmunosuppressive AgentsIncidenceLymphoma, B-Cell, Marginal ZoneLymphoma, Mantle-CellMaleMiddle AgedRetrospective StudiesRisk FactorsRituximabVaccinationVirus Activation